Activity of Oritavancin and Its Synergy with Other Antibiotics against Infection In Vitro and In Vivo.

BACKGROUND

Pulmonary disease caused by () spreads around the world, and this disease is extremely difficult to treat due to intrinsic and acquired resistance of the pathogen to many approved antibiotics. is regarded as one of the most drug-resistant mycobacteria, with very limited therapeutic options.

METHODS

Whole-cell growth inhibition assays was performed to screen and identify novel inhibitors. The IC of the target compounds were tested against THP-1 cells was determined to calculate the selectivity index, and then time-kill kinetics assay was performed against . Subsequently, the synergy of oritavancin with other antibiotics was evaluated by using checkerboard method. Finally, in vivo efficacy was determined in an immunosuppressive murine model simulating infection.

RESULTS

We have identified oritavancin as a potential agent against . Oritavancin exhibited time-concentration dependent bactericidal activity against and it also displayed synergy with clarithromycin, tigecycline, cefoxitin, moxifloxacin, and meropenem in vitro. Additionally, oritavancin had bactericidal effect on intracellular . Oritavancin significantly reduced bacterial load in lung when it was used alone or in combination with cefoxitin and meropenem.

CONCLUSIONS

Our in vitro and in vivo assay results indicated that oritavancin may be a viable treatment option against infection.